OK Erthang, lets talk about your conjecture for a while.
"For one thing Abbott has been working on incorporating the recaf technology into their architect system for almost 2 years, which tells me that they have invested much more $ than the announced $200,000 upfront payment into developing the technology. It's more like a few million."
You have no idea how much they have spent. A few million is wild conjecture on your part.
"They are getting very close to commercialization."
Totally wild conjecture. You have ZERO idea as to what commercialization even is nor when it will occur. Commercialization is having a product for sale and how many years is that away. Even I cannot guess on that. Was Lebed your source of that information? I seem to remember him sayig that in one of his tremendously informative "alerts".
"They have already change the format of the test into a working prototype that is close to being as effective as the original, which used the undesirable radio-active material."
I will let Moro answer that.
"This breakthrough brings us one step closer to the commercialization of our unique cancer test. We have more work to be done to optimize the assay for improved detection comparable to our radioimmunoassay results. We will need to test more samples before we are finished, and there are also other colorimetric formats that we want to implement as well."
He is saying that more work is needed and they will even look at other color formats. IMO, if they are still looking at other formats, Abbott may not even be close to selecting a color format for their analyzer.
Another interesting fact. Small cap did not even comment on the stock during all this hype other than to say that RECAF would be discussed on the TV show. They were wisely silent on all the rest.
News 
Market Data 
Discover 
